dada2 FOUNDATION

The Inaugural International Conference on Deficiency of ADA2

Agenda

FRIDAY, NOVEMBER 11, 2016

7:00 am to 7:50 am	Registration and Continental Breakfast
8:00 am to 8:15 am	Welcome/Introductions/Agenda Overview ***Chip Chambers, M.D. - Founder & President DADA2 Foundation*** ***Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health***

SESSION 1: CLINICAL PRESENTATIONS/PHENOTYPES

8:15 am to 8:40 am	NIH Cohort Experience (Stroke/Liver Phenotype) ***Amanda Ombrello, M.D. - NIH, NHGRI***
8:40 am to 9:05 am	Israel Cohort Experience (PAN Phenotype) ***Yackov Berkun, M.D. - Hadassah Hebrew University Medical Center, Jerusalem, Israel***
9:05 am to 9:25 am	Italy Cohort Experience (B cell Phenotype) ***Marco Gattorno, M.D. - Giannina Gaslini Institute, Genoa, Italy***
9:25 am to 9:45 am	Pure Red Cell Aplasia (Bone Marrow Failure Phenotype) ***Alison Bertuch, M.D., Ph.D. - Texas Children's Hospital/Baylor College of Medicine***
9:45 am to 10:00 am	COFFEE BREAK and NETWORKING
10:00 am to 10:20 am	Finnish Cohort (Malignancy Phenotype) ***Janna Saarela, M.D., Ph.D. - Institute for Molecular Medicine, Helsinki, Finland***
10:20 am to 10:50 am	Oral Abstract Presentations
10:20 am to 10:30 am	B Cells in DADA2 a Monocyte-Derived Antibody Deficiency ***Michele Proeitti, Ph.D. - Center for Chronic Immunodeficiency, Freiburg, Germany***
10:30 am to 10:40 am	Spectrum of Peripheral Blood Findings and Bone Marrow Pathology in DADA2 ***Jaya Balakrishna, M.D. - Department of Laboratory Medicine – Hematopathology, NIH***
10:40 am to 10:50 am	Screening of 180 CVID Patients for DADA2 Sheds New Light on the Disease in Adulthood ***Johanna Schepp, M.D. - Center for Chronic Immunodeficiency, Freiburg, Germany***

SESSION 2: DIAGNOSTIC / SCREENING APPROACH

10:50 am to 11:10 am	Screening for ADA2 Protein and Activity ***Mike Hershfield, M.D. – Duke University School of Medicine***
11:10 am to 11:30 am	Range of ADA2 in Normal Individuals/English Cohort Experience ***Paul Brogan, MB.ChB., Ph.D. - Great Ormond Street Hospital, London, England***
11:30 am to 11:50 am	Genetic Screening for DADA2 ***Ivona Aksentijevich, M.D. - NIH/NHGRI***
11:50 am to 12:10 pm	PICK UP LUNCH/STRETCH BREAK
12:10 pm to 1:10 pm	Panel/Open Mic Discussion/Questions (1 hour)

SESSION 3: MOLECULAR MECHANISMS

1:10 pm to 1:35 pm	What Does ADA2 do? Is Adenosine Deaminase Function Important? ***Andrey Zavialov, Ph.D. - Turku Centre for Biotechnology, Turku, Finland***
1:35 pm to 1:55 pm	Do Type I Interferons Play a Role in DADA2? ***Alexandre Belot, M.D., Ph.D. - Hospices Civils de Lyon, Lyon, France***
1:55 pm to 2:15 pm	Vascular Endothelium & the ADA2 Molecule ***Sonia Sharma, Ph.D. - La Jolla Institute of Allergy and Immunology***
2:15 pm to 2:45 pm	Oral Abstract Presentations
2:15 pm to 2:25 pm	A New Validation Method Proves that ADA2 is a Lysosomal Protein ***Ole Kristian Greiner-Tollersrud, Ph.D*. -** Institute of Medical Biology University of Tromsø, Norway
2:25 pm to 2:35 pm	ADA2 Deficiency Attenuates M2 Macrophages Differentiation ***Dan Yang, M.D., Ph.D. - NHLBI, NIH***
2:35 pm to 2:45 pm	Role of Adenosine and Neutrophils in Deficiency of Adenosine Deaminase 2 ***Carmelo Carmona-Rivera, Ph.D. - NIAMS, NIH***
2:45 pm to 3:00 pm	COFFEE BREAK and NETWORKING

SESSION 4: TREATMENT

3:00 pm to 3:20 pm	Supportive Care / Recommended Screening Labs / Studies ***Debbie Stone, M.D. - NIH/NHGRI***
3:20 pm to 3:40 pm	Bone Marrow Transplant ***Isabelle Meyts, M.D., Ph.D. - University Hospitals Gasthuisberg, Leuven, Belgium***
3:40 pm to 4:00 pm	The Experience of Gene Therapy for ADA1 and it's Potential for DADA2 ***Maria Pia Cicalese, M.D., Ph.D. - San Raffaele Institute for Gene Therapy, Milan, Italy***
4:00 pm to 4:20 pm	Potential for PEG-ADA2 Therapy ***Chris Thanos, Ph.D. - Halozyme Inc., San Diego, California***
4:20 pm to 4:40 pm	Oral Abstract Presentations
4:20 pm to 4:30 pm	ADA2 Deficiency Presenting as Bone Marrow Failure in Adulthood ***Mark Hannibal, M.D., Ph.D. – University of Michigan Medical School***

4:30 pm to 4:40 pm	Successful Reduced Intensity HSCT in A Patient with Refractory Pure Red Cell Aplasia Due to DADA2 ***Hasan Hashem, M.D. - Nationwide Children's Hospital***
4:40 pm to 5:40 pm	Panel/Open Mic Discussion/Questions/Next Steps (1 hour)

SESSION 5: JOINT PHYSICIANS/SCIENTISTS & PATIENTS/FAMILIES

5:40 pm to 6:00 pm	SUMMARY OF THE DAY ***Dan Kastner, M.D., Ph.D. - Scientific Director NHGRI, National Institutes of Health***
6:00 pm to 7:00 pm	JOINT RECEPTION FOR PHYSICIANS/SCIENTISTS & PATIENTS/FAMILIES